Cargando…
Increased Risk of Cutaneous Diseases in Multiple Myeloma Patients
Introduction Multiple myeloma (MM) is a monoclonal gammopathy characterized by malignant proliferation of plasma cells in the bone marrow, leading to the overproduction of monoclonal immunoglobulins. Knowledge of cutaneous findings associated with multiple myeloma is limited. This study aims to char...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7549871/ https://www.ncbi.nlm.nih.gov/pubmed/33062479 http://dx.doi.org/10.7759/cureus.10356 |
_version_ | 1783592866066464768 |
---|---|
author | Buntinx-Krieg, Talayesa McKee, Ryan M Eichenfield, Dawn Z Marsch, Amanda |
author_facet | Buntinx-Krieg, Talayesa McKee, Ryan M Eichenfield, Dawn Z Marsch, Amanda |
author_sort | Buntinx-Krieg, Talayesa |
collection | PubMed |
description | Introduction Multiple myeloma (MM) is a monoclonal gammopathy characterized by malignant proliferation of plasma cells in the bone marrow, leading to the overproduction of monoclonal immunoglobulins. Knowledge of cutaneous findings associated with multiple myeloma is limited. This study aims to characterize cutaneous manifestations in patients with MM or monoclonal gammopathy of undetermined significance (MGUS). Methods This is a retrospective study of patients seen at a single institution between January 2000 and January 2019 with a diagnosis of “multiple myeloma,” “monoclonal gammopathy of undetermined significance,” or “smoldering myeloma,” and an on-site dermatology clinic visit. Results Twenty patients met the inclusion criteria. Most patients were male and Caucasian. Comorbid cutaneous malignancies were noted in 65% of patients (n = 13). Basal cell carcinoma (BCC) was characterized in 55% of patients (n = 11), followed by squamous cell carcinoma in 50% of patients (n = 10), and melanoma in 10% of patients (n = 2). Conclusions Patients with monoclonal gammopathy may be predisposed to developing cutaneous malignancies and skin infections. Given the low prevalence of monoclonal gammopathy, larger multi-center studies with a control cohort may be necessary to delineate the significance of these comorbid skin conditions. |
format | Online Article Text |
id | pubmed-7549871 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-75498712020-10-13 Increased Risk of Cutaneous Diseases in Multiple Myeloma Patients Buntinx-Krieg, Talayesa McKee, Ryan M Eichenfield, Dawn Z Marsch, Amanda Cureus Dermatology Introduction Multiple myeloma (MM) is a monoclonal gammopathy characterized by malignant proliferation of plasma cells in the bone marrow, leading to the overproduction of monoclonal immunoglobulins. Knowledge of cutaneous findings associated with multiple myeloma is limited. This study aims to characterize cutaneous manifestations in patients with MM or monoclonal gammopathy of undetermined significance (MGUS). Methods This is a retrospective study of patients seen at a single institution between January 2000 and January 2019 with a diagnosis of “multiple myeloma,” “monoclonal gammopathy of undetermined significance,” or “smoldering myeloma,” and an on-site dermatology clinic visit. Results Twenty patients met the inclusion criteria. Most patients were male and Caucasian. Comorbid cutaneous malignancies were noted in 65% of patients (n = 13). Basal cell carcinoma (BCC) was characterized in 55% of patients (n = 11), followed by squamous cell carcinoma in 50% of patients (n = 10), and melanoma in 10% of patients (n = 2). Conclusions Patients with monoclonal gammopathy may be predisposed to developing cutaneous malignancies and skin infections. Given the low prevalence of monoclonal gammopathy, larger multi-center studies with a control cohort may be necessary to delineate the significance of these comorbid skin conditions. Cureus 2020-09-10 /pmc/articles/PMC7549871/ /pubmed/33062479 http://dx.doi.org/10.7759/cureus.10356 Text en Copyright © 2020, Buntinx-Krieg et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Dermatology Buntinx-Krieg, Talayesa McKee, Ryan M Eichenfield, Dawn Z Marsch, Amanda Increased Risk of Cutaneous Diseases in Multiple Myeloma Patients |
title | Increased Risk of Cutaneous Diseases in Multiple Myeloma Patients |
title_full | Increased Risk of Cutaneous Diseases in Multiple Myeloma Patients |
title_fullStr | Increased Risk of Cutaneous Diseases in Multiple Myeloma Patients |
title_full_unstemmed | Increased Risk of Cutaneous Diseases in Multiple Myeloma Patients |
title_short | Increased Risk of Cutaneous Diseases in Multiple Myeloma Patients |
title_sort | increased risk of cutaneous diseases in multiple myeloma patients |
topic | Dermatology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7549871/ https://www.ncbi.nlm.nih.gov/pubmed/33062479 http://dx.doi.org/10.7759/cureus.10356 |
work_keys_str_mv | AT buntinxkriegtalayesa increasedriskofcutaneousdiseasesinmultiplemyelomapatients AT mckeeryanm increasedriskofcutaneousdiseasesinmultiplemyelomapatients AT eichenfielddawnz increasedriskofcutaneousdiseasesinmultiplemyelomapatients AT marschamanda increasedriskofcutaneousdiseasesinmultiplemyelomapatients |